

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*  
**22-387**

**STATISTICAL REVIEW(S)**



U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Pharmacoeconomics and Statistical Science  
Office of Biostatistics

## STATISTICAL REVIEW AND EVALUATION

### CLINICAL STUDIES

**NDA/Serial Number:** 22-387  
**Drug Name:** Inhaled treprostinil sodium  
**Indication(s):** Treatment of pulmonary arterial hypertension  
**Applicant:** United Therapeutics Corporation  
**Date(s):** June 27, 2008  
**Review Priority:** Standard

**Biometrics Division:** Biometrics I (HFD-710)  
**Statistical Reviewer:** John Lawrence  
**Concurring Reviewers:** Jim Hung

**Medical Division:** Division of Cariorenal Drug Products (HFD-110)  
**Clinical Team:** Abraham Karkowsky, Medical Reviewer  
**Project Manager:** Dan Blum

**Keywords:** Nonparametric ANCOVA

## Table of Contents

<b>1. EXECUTIVE SUMMARY .....</b>	<b>3</b>
1.1 CONCLUSIONS AND RECOMMENDATIONS .....	3
1.2 BRIEF OVERVIEW OF CLINICAL STUDIES .....	3
1.3 STATISTICAL ISSUES AND FINDINGS .....	3
<b>2. INTRODUCTION .....</b>	<b>4</b>
2.1 OVERVIEW .....	4
2.2 DATA SOURCES .....	6
<b>3. STATISTICAL EVALUATION .....</b>	<b>6</b>
3.1 EVALUATION OF EFFICACY .....	6
3.2 EVALUATION OF SAFETY .....	9
<b>4. FINDINGS IN SPECIAL/SUBGROUP POPULATIONS .....</b>	<b>10</b>
4.1 GENDER, RACE AND AGE .....	10
4.2 OTHER SPECIAL/SUBGROUP POPULATIONS .....	10
<b>5. SUMMARY AND CONCLUSIONS .....</b>	<b>10</b>
5.1 STATISTICAL ISSUES AND COLLECTIVE EVIDENCE .....	10
5.2 CONCLUSIONS AND RECOMMENDATIONS .....	11

## 1. EXECUTIVE SUMMARY

### 1.1 Conclusions and Recommendations

The primary endpoint of the study was change in exercise capacity at Week 12, as measured by the Peak 6MWD. A nonparametric analysis of covariance (ANCOVA), adjusted for baseline walk and disease etiology was performed for all patients. In the treated group, the median change from baseline was 22 m compared to a median improvement of 3 m in the placebo group ( $p=0.004$ , estimated difference of 20 m with a 95% confidence interval of (8, 33)). According to the sponsor's study report, the treatment was well-tolerated and has an acceptable safety profile.

### 1.2 Brief Overview of Clinical Studies

This clinical program included 1 phase 3 safety and efficacy study. This was an international, double blind, multi-center, randomized, placebo controlled, parallel-group study in NYHA Class III and IV adult patients with severe PAH on a stable dose of 125 mg twice daily (BID) of bosentan or a stable dose of sildenafil for at least three months prior to study start. Patients were required to have a Baseline six-minute walk distance (6MWD) of 200-450 meters. This study consisted of a Baseline Visit and a Treatment Period, for a total of 12 weeks. The primary endpoint was the placebo corrected change in distance walked at 12 weeks compared to Baseline in the peak six-minute walk distance (6MWD). Peak 6MWT was assessed no less than ten minutes and no more than 60 minutes post study drug inhalation. All 6MWTs were scheduled to be performed 3-5 hours after the bosentan dose or 30 to 120 minutes after the sildenafil dose. These time periods correspond to the peak plasma concentrations for each of these concomitant therapies.

### 1.3 Statistical Issues and Findings

The primary endpoint, median change in 6MWD was analyzed using a nonparametric analysis of covariance (ANCOVA), with adjustment for etiology and baseline 6MWD. In the treated group, the median change from baseline was 22 m compared to a median improvement of 3 m in the placebo group ( $p=0.004$ , estimated difference of 20 m with a 95% confidence interval of (8, 33)).

The secondary endpoints were analyzed in the following pre-specified hierarchy to control the Type I error rate: time to clinical worsening, Borg dyspnea score, NYHA functional class, trough 6MWD at Week 12, Peak 6MWD at Week 6, quality of life, signs and symptoms of PAH, and Peak 6MWD at Day 1. Four subjects in the treated group and 6 subjects in the placebo group experienced clinical worsening. There was no difference in the time to clinical worsening between treatment groups ( $p=0.5829$ ).

## 2. INTRODUCTION

### 2.1 Overview

This clinical program included 1 phase 3 safety and efficacy study. This was an international, double blind, multi-center, randomized, placebo controlled, parallel-group study in NYHA Class III and IV adult patients with severe PAH on a stable dose of 125 mg twice daily (BID) of bosentan or a stable dose of sildenafil for at least three months prior to study start. Patients were required to have a Baseline six-minute walk distance (6MWD) of 200-450 meters. This study consisted of a Baseline Visit and a Treatment Period, for a total of 12 weeks. The primary endpoint was the placebo corrected change in distance walked at 12 weeks compared to Baseline in the peak six-minute walk distance (6MWD). Peak 6MWT was assessed no less than ten minutes and no more than 60 minutes post study drug inhalation. All 6MWTs were scheduled to be performed 3-5 hours after the bosentan dose or 30 to 120 minutes after the sildenafil dose. These time periods correspond to the peak plasma concentrations for each of these concomitant therapies.

The baseline demographics of the 235 patients studied are in Table 1. There do not appear to be any significant differences between the groups with respect to these variables. The mean age is about 55, the majority are female and NYHA Class III. About 2/3 were taking bosentan and the remainder were taking sildenafil as background therapy.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.